Heart failure (HF) is a global health issue affecting at least 26 million people worldwide, with increasing prevalence. It is a significant burden on healthcare systems, with health expenditures expected to rise sharply due to an aging population. Despite advances in treatment and prevention, mortality and morbidity remain high, and quality of life is poor. HF is classified into three subtypes based on ejection fraction: HF with reduced ejection fraction (HFrEF), HF with preserved ejection fraction (HFpEF), and HF with mid-range ejection fraction (HFmrEF). Global prevalence of HF varies by region, with higher rates in older populations and in certain areas like Asia. In the US, over 5.7 million people have HF, with projections indicating a 46% increase by 2030. In Europe, HF prevalence ranges from 1.36% in younger adults to 16.14% in those over 80. In Germany, the prevalence is 1.6% in women and 1.8% in men. In Sweden, the prevalence is 1.8%, with higher rates in older individuals. In Asia, HF prevalence ranges from 1.3% to 6.7%, with China having 4.2 million cases and Japan around 1 million. In South America, the prevalence is 1%, and in Australia, it ranges between 1% and 2%. HF incidence also varies globally, with higher rates in older populations and men. In the US, the incidence is around 10 per 1,000 population after 65 years of age. In Portugal, the incidence is 1.3 cases per 1,000 population per year for those aged 25 and older, increasing to 8.8 per 1,000 for those over 65. In the UK, the incidence is 4.4 per 1,000 in men and 3.9 in women. In Spain, the incidence increased from 2.96 to 3.90 cases per 1,000 population per year between 2000 and 2007. In Germany, the incidence is 2.7 cases per 1,000 population per year. HF is associated with significant morbidity and mortality, with higher rates in HFrEF compared to HFpEF. In the US, 60–90-day mortality rates are similar between HFrEF and HFpEF, but in-hospital mortality is higher in HFrEF. In Europe, the 90-day mortality rate is higher in HFrEF compared to HFpEF. HFpEF is becoming more prevalent, with a growing proportion of patients having HFpEF. HF outcomes are worse in many regions, with higher mortality rates inHeart failure (HF) is a global health issue affecting at least 26 million people worldwide, with increasing prevalence. It is a significant burden on healthcare systems, with health expenditures expected to rise sharply due to an aging population. Despite advances in treatment and prevention, mortality and morbidity remain high, and quality of life is poor. HF is classified into three subtypes based on ejection fraction: HF with reduced ejection fraction (HFrEF), HF with preserved ejection fraction (HFpEF), and HF with mid-range ejection fraction (HFmrEF). Global prevalence of HF varies by region, with higher rates in older populations and in certain areas like Asia. In the US, over 5.7 million people have HF, with projections indicating a 46% increase by 2030. In Europe, HF prevalence ranges from 1.36% in younger adults to 16.14% in those over 80. In Germany, the prevalence is 1.6% in women and 1.8% in men. In Sweden, the prevalence is 1.8%, with higher rates in older individuals. In Asia, HF prevalence ranges from 1.3% to 6.7%, with China having 4.2 million cases and Japan around 1 million. In South America, the prevalence is 1%, and in Australia, it ranges between 1% and 2%. HF incidence also varies globally, with higher rates in older populations and men. In the US, the incidence is around 10 per 1,000 population after 65 years of age. In Portugal, the incidence is 1.3 cases per 1,000 population per year for those aged 25 and older, increasing to 8.8 per 1,000 for those over 65. In the UK, the incidence is 4.4 per 1,000 in men and 3.9 in women. In Spain, the incidence increased from 2.96 to 3.90 cases per 1,000 population per year between 2000 and 2007. In Germany, the incidence is 2.7 cases per 1,000 population per year. HF is associated with significant morbidity and mortality, with higher rates in HFrEF compared to HFpEF. In the US, 60–90-day mortality rates are similar between HFrEF and HFpEF, but in-hospital mortality is higher in HFrEF. In Europe, the 90-day mortality rate is higher in HFrEF compared to HFpEF. HFpEF is becoming more prevalent, with a growing proportion of patients having HFpEF. HF outcomes are worse in many regions, with higher mortality rates in